Ultragenyx Pharmaceutical (RARE) Intangibles (2017 - 2026)
Ultragenyx Pharmaceutical (RARE) posted quarterly Intangibles of $174.0 million for Q1 2026, down 1.43% year-over-year from $176.5 million in Q1 2025, and down 1.14% quarter-over-quarter from $176.0 million in Q4 2025.
Ultragenyx Pharmaceutical (RARE) Intangibles (2017 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Intangibles for 10 consecutive years, with $174.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Intangibles fell 1.43% year-over-year to $174.0 million; the TTM figure through Mar 2026 stood at $174.0 million (down 1.43% YoY), while the FY2025 annual figure was $176.0 million, down 1.12% from the prior year.
- Intangibles eased to $174.0 million in Q1 2026 per RARE's latest filing, from $176.0 million in the prior quarter.
- Across five years, Intangibles topped out at $178.0 million in Q4 2024 and bottomed at $157.3 million in Q3 2023.
- Historically, Intangibles has averaged $166.7 million across 5 years, with a median of $165.0 million in 2024.
- Annual changes were most pronounced in 2022 — Intangibles grew 22.42% — and 2026, when it slipped 1.43%.
- Ultragenyx Pharmaceutical's Intangibles stood at $160.1 million in 2022, then climbed by 8.54% to $173.8 million in 2023, then grew by 2.43% to $178.0 million in 2024, then declined by 1.12% to $176.0 million in 2025, then fell by 1.14% to $174.0 million in 2026.
- Business Quant data shows RARE's Intangibles at $174.0 million in Q1 2026, $176.0 million in Q4 2025, and $172.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.61 Bn | 2.33 Bn | 180.00 Mn | 172.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 172.00 Mn |
| Mar 31, 2026 | 174.00 Mn |
| Dec 31, 2025 | 176.00 Mn |
| Sep 30, 2025 | 172.94 Mn |
| Jun 30, 2025 | 174.73 Mn |
| Mar 31, 2025 | 176.52 Mn |
| Dec 31, 2024 | 178.00 Mn |
| Sep 30, 2024 | 164.94 Mn |
| Jun 30, 2024 | 166.24 Mn |
| Mar 31, 2024 | 165.05 Mn |
| Dec 31, 2023 | 173.78 Mn |
| Sep 30, 2023 | 157.30 Mn |
| Jun 30, 2023 | 158.24 Mn |
| Mar 31, 2023 | 159.17 Mn |
| Dec 31, 2022 | 160.11 Mn |
| Sep 30, 2022 | 158.40 Mn |
| Jun 30, 2022 | 159.20 Mn |
| Mar 31, 2022 | 159.99 Mn |
| Dec 31, 2021 | 130.79 Mn |
| Sep 30, 2021 | 130.87 Mn |